Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Fluzone: Influenza virus vaccine · 1 trial · 1 indication
Pain or other discomfort was assessed on a scale of 0 to 10 (None = 0; Hardly Any = 1, 2; Mild = 3, 4; Moderate = 5, 6; Severe = 7, 8; Unbearable = 9, 10) according to route of administration: intradermal (ID) as Group 1 and intramuscular (IM) as Group 2. Data for this outcome were combined for responses following a similar type of vaccination route in the entire study population.
Numerical scores were assigned to pain by participants on the preference questionnaire as: None = 0; Hardly Any = 1, 2; Mild = 3, 4; Moderate = 5, 6; Severe = 7, 8; or Unbearable = 9, 10. Data for this outcome were combined for responses following a similar type of vaccination route in the entire study population.
| Arm | Type | Description |
|---|---|---|
| Fluzone Intradermal First, Then Fluzone Intramuscular | EXPERIMENTAL | - |
| Fluzone Intramuscular First, Then Fluzone Intradermal | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Fluzone: Influenza virus vaccine | BIOLOGICAL | 0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid |
Inclusion Criteria: * Healthy male or female subject (can have underlying medical condition, as long as they are stable), greater than or equal to 18 to \< 50 years of age on the day of inclusion. * Informed consent form signed. * Able to attend both scheduled visits and to comply with all trial pr...
Top 6 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 1 | PHASE3 | mRNA-1018-H5 |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
| GSK plc Sponsored ADR | GSK | 1 | PHASE1 | Flu/COVID-19 mRNA combination vaccine |
Fluzone is an influenza virus vaccine developed by Sanofi for the prevention of influenza. It is intended to protect against influenza infection, and clinical development has focused on evaluating different routes of administration in healthy adults.
Fluzone is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer of this influenza virus vaccine and conducted the clinical study evaluating its use.
Fluzone has been studied in Phase 2 clinical development for influenza. The completed trial was a Phase 2 study, and there are no active trials listed for this vaccine candidate.
Fluzone was evaluated in a completed Phase 2 trial, NCT00623181, titled a study to determine a preference for Fluzone vaccine given intradermally and intramuscularly in healthy adults. The trial enrolled 110 participants in the United States and was controlled and randomized.
In the completed Phase 2 trial NCT00623181, Fluzone was given both intradermally and intramuscularly to healthy adults to determine a preference between the two routes. The study enrolled 110 participants aged 18 years and older in the United States.